Ansgar Santel
Chief Executive Officer Pantherna Therapeutics
Ansgar Santel is Chief Executive Officer at Pantherna Therapeutics, leading the translation of new mRNA therapeutic concepts into clinical application. With expertise in preclinical mRNA-LNP development and strategic collaborations, he drives innovation in expanding therapeutic indications and advancing next-generation mRNA medicines.
Seminars
Friday 19th February 2027
Panel Discussion: Positioning mRNA Programmes to Attract Investment & Strategic Partnerships
8:00 am
- Addressing investor expectations: balancing early-stage innovation with clinical validation requirements
- Understanding how political & regulatory headwinds impact RNA therapeutic investment (vaccine hesitancy, government funding changes)
- Navigating the tension between long-term scientific development & short-term investor exit timelines
Friday 19th February 2027
Panel Discussion: Defining the Most Valuable Use Cases for mRNA-LNP Therapeutics: Prioritising Applications with the Greatest Clinical & Commercial Potential
4:00 pm
- Identifying “sweet spots” for mRNA-LNP therapeutics based on dosing frequency, administration route & immune considerations
- Focusing development on validated applications: Cancer vaccines, infectious disease vaccines, protein replacement & in vivo CAR-T
- Learning from clinical setbacks to understand biological & commercial limitations of the platform
